Viking Therapeutics Director Dorothy Kelly‑Gemmell Receives Award

What Happened

• Dorothy Elizabeth Kelly‑Gemmell, a director of Viking Therapeutics (VKTX), was granted two equity awards on Aug 1, 2026: 6,333 restricted stock units (RSUs) and a derivative award covering 40,800 shares. Both entries show an acquisition price of $0.00, indicating these were compensation awards rather than open‑market purchases.

Key Details

• Transaction date: 2026-08-01; Form 4 filed: 2026-08-07.
• Awards: 6,333 RSUs (grant) and 40,800‑share derivative award (option/other equity grant), both reported as acquisitions at $0.00.
• Vesting: RSU award vests one‑third on each anniversary of the grant date (footnote F1). The derivative award similarly vests one‑third on each anniversary (footnote F2).
• Shares owned after transaction: Not specified in the provided filing.
• No sale or exercise occurred; this is a grant/compensation event, not a purchase or disposition.
• No 10b5-1 plan, tax‑withholding sale, or late‑filing flag was provided in the summary data. Investors can compare the Aug 7 filing date to the two‑business‑day Form 4 deadline if timeliness is a concern.

Context

• Grants at $0 are standard for RSUs and option awards as part of director or executive compensation and do not reflect an immediate cash outlay by the insider.
• Because vesting is staggered (one‑third per year), the economic benefit is realized over time only if vesting conditions are met. This is a compensation event, not a sign of immediate buying or selling activity.